InvestorsHub Logo
Followers 19
Posts 1098
Boards Moderated 0
Alias Born 03/27/2013

Re: Lima4918 post# 207652

Thursday, 08/29/2019 9:08:50 AM

Thursday, August 29, 2019 9:08:50 AM

Post# of 466650
Just to keep this topic warm, I'd like to add an excerpt from the Q3 transcript...

"Lastly, a recent third-party peer reviewed scientific publication titled Neuronal Sigma-1 Receptor signaling functions and protective roles in neurodegenerative diseases, details the mechanism of action of sigma-1 receptor, S1R and references ANAVEX 2-73 among the relevant sigma-1 receptor ligands.

The paper summarizes, in conclusion, sigma-1 receptor is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders. We believe that this comment is a confirmation that Anavex is on the right track pursuing this very promising therapeutic approach for targeting patients with devastating rare diseases as well as the largest unmet medical need of aging population, which is Alzheimer’s disease and Parkinson’s disease."

Sure seems to me like the company sometimes comments on articles from third parties.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News